Medicines for Malaria Venture (MMV)

14/11/2025

🌍 Together with the Coalition for Epidemic Preparedness Innovations (CEPI), Drugs for Neglected Diseases initiative (DNDi) and Unitaid, we are pleased to welcome the Belém Health Action Plan (BHAP), developed under Brazil’s leadership to strengthen health systems in the face of .

Climate change is a global health emergency, with climate-sensitive diseases spreading rapidly and disproportionately affecting vulnerable communities. Urgent, equitable and coordinated action is essential.

We commend BHAP’s focus on equity, climate justice and inclusive governance. We also welcome its commitment to fostering research, innovation and equitable access to health tools, which are important steps to better prepare for and respond to climate-sensitive diseases.

🤝 Drawing on our collective experience of developing and delivering solutions for dengue, , chikungunya, leishmaniasis, Rift Valley Fever, and other climate-sensitive diseases, we stand ready to support the implementation of the BHAP and contribute our expertise across prevention, testing and treatment.

Read our joint statement and action plan: bit.ly/43swhX4

COP30 Brazil

13/11/2025

For the first time in 25 years, a new class of treatment is within reach.

Today, Novartis and MMV announced positive Phase 3 results for GanLum, a novel, non-artemisinin medicine with an entirely new mechanism of action and the potential to kill drug-resistant parasites and block transmission.

Next step: Novartis plans to seek regulatory approval from health authorities as soon as possible.

12/11/2025

From a seed planted by the Gates Foundation in 2019 to a strong global partnership supported by Unitaid, the Partnership for Vivax Elimination (PAVE) has generated valuable evidence and shared knowledge across its network to reshape the way radical cure for vivax is being delivered.

This week at , PAVE partners were on hand to share how real-world research is strengthening malaria control and elimination efforts at both country and global levels:

🔹Evidence through feasibility studies: PAVE has demonstrated that optimized radical cure can be delivered across diverse health systems.
🔹Translating feasibility to policy: Data generated has supported decisions among Ministries of Health and helped inform global implementation guidelines.
🔹From policy to impact: As PAVE partner countries adopt new tools, they are expanding access to critical interventions and paving the way for others to do the same.

PAVE has demonstrated what’s possible when evidence, partnerships and policy align to turn innovative tools and collaborative research into real-world impact.

12/11/2025

We are the impatient optimists who believe in eradication in our lifetime.

Today at , MMV and the Gates Foundation convened leading global health experts to reaffirm their shared belief in a malaria-free future and chart a bold, science-driven course to get the elimination agenda back on track.

The message was clear:

🔹 Transformative tools will help us bend the curve in the race towards zero malaria deaths.
🔹 Resilience, partnerships and persistence are the keys to success.
🔹 From lives saved to returns on investment – we cannot afford to lose the fight against malaria.

Stay tuned for the video recording of this sponsored symposium.

12/11/2025

🏅 MMV is officially an awardee for Action for Women’s Health, a global open call funded by Pivotal Ventures and managed by LeverforChange.

We are honoured to have been selected as one of 80+ organizations, identified among a total of 4,000 from 119 countries.

Founded by Melinda French Gates in 2015, Pivotal works to advance social progress and expand women's power and influence in the U.S. and around the world.

This milestone reinforces MMV’s commitment to advancing women’s health in the fight against – especially for pregnant and breastfeeding women – through research and development of appropriate antimalarials.

With these new resources and through the MiMBa initiative, we’re ready to accelerate progress towards targeted treatment options and better care for mothers and babies.

Read more: bit.ly/4nTrzsW

hashtag hashtag

The high-profile donor grant will enable MMV to scale up its Malaria in Mothers and Babies (MiMBa) initiative to transform women’s health beyond malaria.

10/11/2025

MMV is at !

Meet us in the exhibition hall at our booth (512) – come for the Swiss chocolate and Italian coffee, stay for chats about our work and partnerships helping advance the elimination agenda.

Check out our digital leaflet for more info on MMV and partner activities taking place this week: bit.ly/4hSZTmC

07/11/2025

Heading to in Toronto? 🇨🇦✨

So is MMV! We’re looking forward to connecting with colleagues and partners at our booth ( #512) and sharing our latest projects, partnerships and research through several scientific symposia, as well as during the oral and poster presentation sessions.

📘 Explore our digital leaflet for a full overview of MMV and partner activities at the ASTMH Annual Meeting: bit.ly/4hSZTmC

07/11/2025

🎥 How can we shift the traditional mindset of protecting certain patients from research to protecting them through research?

This question was at the heart of a session on underrepresented populations in clinical trials at this year’s Africa Regulatory Conference.

During the session, MMV’s Senior Director of Clinical and Regulatory Science, Myriam El Gaaloul, shared insights from our Malaria in Mothers and Babies (MiMBa) initiative.

Now in its fifth year, MiMBa is working to close healthcare gaps for pregnant and lactating women in -endemic countries and make clinical research more inclusive. Among its key projects is SAFIRE, Africa’s first-ever Phase 3 adaptive platform clinical trial assessing malaria treatments in first-trimester pregnancy.

🎬 Watch the full session, including Myriam’s presentation, here: bit.ly/47p6od3

07/11/2025

🌍 Join us at for an important discussion on and infectious diseases.

Climate change is transforming the landscape of diseases like , dengue, and leishmaniasis, placing billions more people at risk by 2070. Strengthening health systems to respond to these threats is critical to save lives and promote health equity.

Hosted by CEPI, Fiocruz, GAVI, MMV, Unitaid, and DNDi, this event will bring together voices from government, international organizations, philanthropy, multilateral development banks, civil society, and youth. We will showcase innovative solutions, from new product development and delivery strategies to resilient supply chains and community-based care models, that strengthen health system resilience in a changing climate.

📅 Date: Tuesday, 11 November 2025
🕥 Time: 10:30–11:30 BRT (GMT-3)
📍 Venue: COP30 Health Pavilion, Blue Zone

💻 🎥 Livestream: Click here to watch live:👉 https://bit.ly/4qHGskJ

Join us as we work together to identify concrete recommendations to advance the Belem Health Action Plan.

06/11/2025

Staff from MMV are celebrating Malaria Day in the Americas by joining the Brazilian MedTrop Conference in Belém this week!

We congratulate the Brazilian National Malaria Programme and the Ministry of Health for their leadership and success in rolling out single-dose tafenoquine with G6PD testing – a milestone that strengthens radical cure and accelerates progress towards elimination.

This achievement is a testament to Brazil’s commitment to innovation and patient-centered care. We look forward to collaborating further to support the rollout of tafenoquine for children and to continue working alongside the National Programme as it advances towards a malaria-free Brazil.

Together, we can overcome barriers and ensure that every patient has access to effective radical cure.

06/11/2025

While the public health impacts of in endemic regions of Africa are well documented, the personal and socioeconomic toll of the disease remains less visible in broader discourse.

To better contextualize and humanize the malaria burden across sub-Saharan Africa, researchers analyzed a collection of personal testimonials, revealing how the disease shapes daily lives, overwhelms families and perpetuates cycles of poverty.

Read the thematic analysis in the International Journal for Equity in Health: bit.ly/4ngaE3n

05/11/2025

MMV is currently working with the Health and Social Development Organization (HSD) and partners in Cambodia to evaluate and support the country's last-mile elimination efforts.

In September, our Technical Coordinator for the Asia-Pacific region, Manash Shrestha, visited remote study sites where HSD is assessing the operational feasibility, cost and acceptability of these strategies. Community outreach and mobilization are critical to the success of these efforts and help ensure that patients have access to medicines and other prevention tools, like insecticide-treated nets and mosquito sprays.

The visit coincided with the start of qualitative data collection, where a local partner was conducting in-depth interviews with villagers who participated in the interventions, as well as healthcare workers and policymakers. These interviews aim to capture perceptions and challenges – the human side of elimination efforts that often remains hidden behind case counts and coverage rates.